secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azenta, Inc. (AZTA)
CIK:        0000933974
Form:       8-K
Filed at:   2026-10-30T12:02:38+00:00
Accession:  0001628280-26-068443
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Azenta takes exclusive Elegen gene-synthesis license and buys SynPlexity to expand GENEWIZ
--------------------------------------------------------------------------------

- Exclusive, royalty-free license to Elegen's gene synthesis and cell-free cloning patents and know-how; initial five-year term, extendable by mutual agreement.
- Azenta can exercise an option 12-18 months after signing, paying $25M, to convert to an irrevocable, perpetual, exclusive, royalty-free license.
- Aggregate capital deployment of $32M-$71M, depending on future equipment purchases and whether Azenta exercises the perpetual-license option.
- Acquired all outstanding stock of SynPlexity Inc. under an Oct. 28, 2026 Stock Purchase Agreement that closed concurrently; purchase price not disclosed.
- SynPlexity's pooled gene assembly yields thousands of full-length gene variants per library; technology to be folded into the GENEWIZ synthesis portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/933974/000162828026068443/0001628280-26-068443-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/933974/000162828026068443/azta-20261028.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-068443

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer